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Introduction {#sec1}
============

The endoplasmic reticulum (ER) is the intracellular organelle in which most secretory and many transmembrane proteins are folded and assembled in eukaryotic cells ([@bib9], [@bib17], [@bib28]). Early studies revealed that this organelle also stores Ca^2+^ in an ATP-dependent manner ([@bib6]). It is now widely accepted that the ER represents the major intracellular Ca^2+^ reservoir and, thus, it is essential for both protein biogenesis and intracellular Ca^2+^ signaling in the mammalian cell. Generally, the total Ca^2+^ stored in ER are in the order of 1--3 mM and the luminal free Ca^2+^ concentration in ER (\[Ca^2+^\]~ER~) can reach 100--800 μM, which represents more than 1,000-fold of the cytosolic Ca^2+^ concentration (\[Ca^2+^\]~cyt~) at rest ([@bib6]). However, the ER membrane is significantly more leaky than other cell membranes ([@bib18]). Hence Ca^2+^, among other cations, permeates the ER membrane and gives rise to Ca^2+^ leakage from ER as a result of the steep ER-cytosol Ca^2+^ gradient ([@bib5]). Since ER Ca^2+^ leakage can be unmasked by inhibiting sarco/ER Ca^2+^ ATPases (SERCA) in multiple cell types, it is generally assumed that \[Ca^2+^\]~ER~ is maintained by balancing ER Ca^2+^ leakage and ATP-dependent Ca^2+^ influx into the ER via SERCA pumps ([@bib5], [@bib6]). The molecular structure of Ca^2+^ leak channels in the ER has not yet been fully elucidated ([@bib5]), but it is remarkable that the ubiquitously expressed Sec61 complex has been identified as a high-conductance Ca^2+^-permeable channel that can support Ca^2+^ leakage from the ER ([@bib32], [@bib19], [@bib42], [@bib34], [@bib12]). The core of the Sec61 complex consists of Sec61α, Sec61β, and Sec61γ, where Sec61α forms a protein-conducting channel that facilitates the translocation of secretory and transmembrane proteins into the ER ([@bib17]). Apparently, Sec61 complexes become Ca^2+^ permeable only after protein translocation and the resulting Sec61-mediated Ca^2+^ leakage is limited by cytosolic Ca^2+^-calmodulin and the ER luminal chaperone immunoglobulin heavy-chain binding protein under physiological conditions ([@bib12], [@bib31]). Given the ubiquitous expression of Sec61 complexes in eukaryotic cells, Sec61-mediated Ca^2+^ leakage is emerging as an important pharmacological target within the field of Ca^2+^ homeostasis. However, little is known about small molecules that modulate ER Ca^2+^ leakage by targeting Sec61 complexes. For instance, puromycin enhances the Sec61-mediated Ca^2+^ leakage ([@bib19], [@bib34], [@bib15]), but, mechanistically, puromycin is a substrate for the ribosomal peptidyltransferase and clears nascent polypeptide chains from protein-conducting channels in the ER membrane ([@bib32]). Some inhibitors of protein translocation across the ER membrane bind directly to the Sec61 complex and stabilize it in a closed state ([@bib35]). With the exception of exotoxin A ([@bib30]), however, it is not known whether Sec61 complexes that have been blocked by translocation inhibitors become permeable or are sealed for Ca^2+^ fluxes.

Eeyarestatin 1 and eeyarestatin 2 (ES1 and ES2) are small molecules that were initially identified as inhibitors of protein dislocation from ER into the cytosol ([@bib13]). Subsequent studies have shown that ES1 is an inhibitor of ER-associated protein degradation (ERAD), which targets the cytosolic AAA-ATPase p97, leading to the accumulation of poly-ubiquitinated ERAD substrates ([@bib37], [@bib39]). Supporting this idea, it has been shown that ES1 is particularly cytotoxic against cancer cells when combined with proteasome inhibitors ([@bib38], [@bib4]). Additional mechanisms that potentially contribute to the cytotoxic effects of ES1 are the impairment of both intracellular vesicular transport and membrane insertion of tail-anchored proteins ([@bib1], [@bib24], [@bib14]). Independently of targeting the ER-cytosol dislocation of proteins, ES1 also inhibits the co-translational translocation of nascent polypeptides into the ER, most likely by inhibiting Sec61 complexes both *in cellula* and *in vitro* ([@bib8]). The ES1-dependent inhibition of protein translocation at the ER leads to an almost complete loss of glycoprotein secretion ([@bib8]) and, after ∼2 h of exposure to ES1, cells also begin to show signs of ER stress in the form of the unfolded protein response ([@bib21]). Thus, ES1 apparently affects ER functions at various levels, including co-translational protein translocation through Sec61 complexes ([@bib8]) and, since Sec61 complexes support Ca^2+^ fluxes through ER membranes ([@bib17]), it can be predicted that ES1 treatment of cells will also impact on ER Ca^2+^ homeostasis. However, whether the ES1-mediated blockade of co-translational translocation is accompanied by the opening or closing of Sec61 complexes to Ca^2+^ ions is unknown. To distinguish between these two possibilities, we monitored the effects of ES1 by imaging both \[Ca^2+^\]~cyt~ and \[Ca^2+^\]~ER~. Surprisingly, we found that ES1 enhanced ER Ca^2+^ leakage and depleted the ER Ca^2+^ store. Using *SEC61A1* gene silencing, we show that ES1 increases Ca^2+^ leakage from ER by targeting Sec61 complexes. By comparing the actions of different ES1 analogs on both protein translocation and Ca^2+^ homeostasis, we pinpointed the structural domain responsible for the effects of ES1 on Sec61 complexes. Hence, ES24, which resembles the 5-NF domain of ES1 and blocks protein translocation *in vitro*, is more effective than the parent compound at enhancing Sec61-mediated Ca^2+^ leakage and is particularly cytotoxic to cells that are sensitive to Ca^2+^-induced cell death. Conversely, the effects of ES24 on cellular ubiquitin homeostasis, and hence its likely impact on protein degradation, are less pronounced than those of ES1. On the basis of these findings, we propose that ES24 and the 5-NF domain of ES1 interact with the lateral gate as a "foot in the door" and capture Sec61 channels in a Ca^2+^-permeable, open state that is translocation incompetent.

Results {#sec2}
=======

ES1 Depletes ER Ca^2+^ by Enhancing Ca^2+^ Leakage from ER {#sec2.1}
----------------------------------------------------------

To obtain an integrated view of the Ca^2+^ status in cells under treatment with ES1, we measured free Ca^2+^ concentrations simultaneously in the ER (\[Ca^2+^\]~ER~) and the cytosol (\[Ca^2+^\]~cyt~) in the absence of extracellular Ca^2+^ to minimize Ca^2+^ entry. \[Ca^2+^\]~ER~ was imaged with the genetically encoded, FRET-based Ca^2+^ sensor D1ER ([@bib25]), which was stably expressed in HEK cells (HEK-D1ER). FURA-2 was used to image \[Ca^2+^\]~cyt~ in the same HEK D1ER cells. To minimize possible secondary effects, such as those resulting from a prolonged ER stress (see [@bib21]), cellular Ca^2+^ levels were analyzed within minutes of ES1 addition in the so-called "online" protocol ([Figure 1](#fig1){ref-type="fig"}). In this approach, we first explored the action of ES1 on \[Ca^2+^\]~cyt~ and \[Ca^2+^\]~ER~. Afterward, we unmasked Ca^2+^ leakage from the ER by blocking SERCA pumps with thapsigargin (TG) and measured the specific effects of ES1 on Ca^2+^ leakage from the ER.Figure 1Eeyarestatin 1 (ES1) Interferes with the Cell Ca^2+^ Homeostasis by Enhancing the Ca^2+^ Leakage from ER in a Dose- and Time-Dependent Manner(A and B) Increasing concentrations of ES1 produced accumulation of Ca^2+^ in cytosol (A), which resulted from the loss of ER (B) Ca^2+^ due to the dose-dependent gain of Ca^2+^ leakage.(C and D) The TG responses in cytosolic Ca^2+^ (C) after short exposures to ES1 reflected the dose-dependent decrease of ER Ca^2+^ (D) and the gain of Ca^2+^ leakage.(E) Surges in \[Ca^2+^\]~cyt~ after TG application were integrated between 1,200 and 1,800 s to obtain the area under the curve (post-TG AUC) for the experiments shown in (A).(F) Decreases of \[Ca^2+^\]~ER~ induced by ES1 in experiments shown in (B) were quantified just before TG application (pre-TG \[Ca^2+^\]~ER~).(G) The Ca^2+^ leakage from ER was estimated by measuring the half-time of the decay in \[Ca^2+^\]~ER~ (post-TG t~1/2~) induced by TG in experiments shown in (B).(H and I) The relative amplitude of \[Ca^2+^\]~cyt~ increases after TG applications (post-TG Δ\[Ca^2+^\]~cyt~) (H) and \[Ca^2+^\]~ER~ levels just before TG application (pre-TG \[Ca^2+^\]~ER~) (I) are shown for the experiments in (C and D).DMSO controls are denoted as mock. Application time points are indicated by vertical lines in (A--D) (mock/ES1; 1μM TG). Data are presented as means ± SEM. n.a., not analyzed; n.s., not significant; \*\*\*p \< 0.001. N = 30--47 cells per experimental setting. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

As shown in [Figure 1](#fig1){ref-type="fig"}A, we observed an increase of \[Ca^2+^\]~cyt~ immediately after application of ES1. Since we minimized extracellular Ca^2+^ entry by using EGTA in the bath solution, the increase of \[Ca^2+^\]~cyt~ induced by ES1 could in principle have resulted from the outflow of Ca^2+^ from intracellular Ca^2+^ stores. It is conceivable that ES1 potentiated the accumulation of ER Ca^2+^ in cytosol by also inhibiting cellular clearance mechanisms. However, all cells treated with 0.1 and 1 μM ES1 successfully removed the large amounts of Ca^2+^ that were released by TG into the cytosol ([Figure 1](#fig1){ref-type="fig"}A). Based on these observations, we suggest that ES1 does not disturb the clearance of Ca^2+^ from the cytosol, at least during the 17-min exposure to the compound. In addition, the fact that TG was largely ineffective after treatment with 10 μM ES1 ([Figure 1](#fig1){ref-type="fig"}A) underpinned the suggestion that ES1 primarily mobilizes Ca^2+^ from TG-sensitive Ca^2+^ stores. This suggestion is further supported by the analysis of \[Ca^2+^\]~ER~ that was measured simultaneously in the same set of cells ([Figure 1](#fig1){ref-type="fig"}B). The loss of ER Ca^2+^ due to EGTA in the bath solution was relatively low before TG application (∼0.75% per min). By contrast, \[Ca^2+^\]~ER~ began to decrease immediately after application of 1--10 μM ES1 ([Figure 1](#fig1){ref-type="fig"}B). Thus, the \[Ca^2+^\]~ER~ imaging experiments strongly suggest that ES1 specifically impaired ER Ca^2+^ homeostasis in a dose-dependent manner. The possible involvement of IP~3~ receptors in the effects of ES1 is unlikely because the decrease of \[Ca^2+^\]~ER~ was also observed in the presence of IP~3~ inhibitors ([Figure S1](#mmc1){ref-type="supplementary-material"}). One possible explanation for this effect is that ES1 might have inhibited SERCA pumps. A second, not necessarily exclusive, explanation is that ES1 might have enhanced Ca^2+^ leakage from the ER. We therefore inhibited SERCA pumps with TG in order to determine the specific effects of ES1 on Ca^2+^ leakage and found that ES1 apparently enhanced the Ca^2+^ leakage rate such that the TG-induced decay of \[Ca^2+^\]~ER~ became faster as the ES1 concentration was increased from 0.1 to 1 μM, suggesting that ES1 induced a dose-dependent gain of Ca^2+^ leakage ([Figure 1](#fig1){ref-type="fig"}B).

When the ER Ca^2+^-efflux-influx equilibrium was broken down by TG, the \[Ca^2+^\]~ER~ decay displayed a typical exponential time course ([Figure 1](#fig1){ref-type="fig"}B), as reported previously (e.g., [@bib22]). Accordingly, the amount of Ca^2+^ running out per unit time, here termed Ca^2+^ leakage, is proportional to the product of \[Ca^2+^\]~ER~ and the Ca^2+^ leak constant, which in turn reflects the fraction of \[Ca^2+^\]~ER~ released per unit time and is directly related to half-time of decay (t~1/2~), i.e., the time required for \[Ca^2+^\]~ER~ to decrease by 50% of the pre-TG level. Since the TG-induced changes in \[Ca^2+^\]~cyt~ likely reflect the Ca^2+^ leakage, it is expected that a time-dependent decrease of \[Ca^2+^\]~ER~ due to enhanced Ca^2+^ leakage will paradoxically reduce cytosolic responses to TG, as is observed for 10 μM ES1 in [Figure 1](#fig1){ref-type="fig"}A. Therefore, we next analyzed the time-dependent effects of ES1 on \[Ca^2+^\]~cyt~ and \[Ca^2+^\]~ER~. Despite the lower \[Ca^2+^\]~ER~ levels, the cytosolic responses to TG were higher in cells treated with 10 μM ES1 for 4 min than in those treated with 1 μM ES1 ([Figure 1](#fig1){ref-type="fig"}C). In 4-min treatments, however, the \[Ca^2+^\]~ER~ levels decayed to lower levels in cells exposed to 10 μM ES1 than in those treated with 1 μM ES1 ([Figure 1](#fig1){ref-type="fig"}D). The most likely explanation for these apparently contradictory results is that 10 μM ES1 enhanced the Ca^2+^ leakage sufficiently strongly to compensate for the reduced \[Ca^2+^\]~ER~ levels, thus giving rise to stronger cytosolic responses to TG. In fact, t~1/2~ of the TG-induced decay of \[Ca^2+^\]~ER~ was 106.61 ± 7.72 and 43.83 ± 2.18 s in cells treated for 4 min with 1 and 10 μM ES1, respectively. Next, we compared the effects of 4- and 17-min exposure with 1 μM ES1. Since \[Ca^2+^\]~ER~ decreased continuously during ES1 exposures, the \[Ca^2+^\]~ER~ levels were significantly lower after a 17-min exposure than after a 4-min exposure to 1 μM ES1 ([Figures 1](#fig1){ref-type="fig"}B and 1D). Surprisingly, however, the cytosolic responses to TG were similar after 4- and 17-min treatments with 1 μM ES1 ([Figures 1](#fig1){ref-type="fig"}A and 1C). Based on the idea that the product of \[Ca^2+^\]~ER~ and Ca^2+^ leakage constant determines the amplitude of cytosolic responses to TG, the most likely explanation for the different responses at 4 and 17 min is that the gain of Ca^2+^ leakage was high enough to support a robust response to TG in cytosol at the end of the 17-min ES1 treatment. In fact, t~1/2~ of the TG-induced decay of \[Ca^2+^\]~ER~ was 106.61 ± 7.72 and 94.20 ± 6.50 s after 4- and 17-min treatments with 1 μM ES1, respectively. Thus, the experiments in [Figures 1](#fig1){ref-type="fig"}C and 1D indicate that ES1 begins to enhance the Ca^2+^ leakage from ER almost immediately after application and this effect is boosted during the treatment in a time-dependent manner.

A quantitative analysis of the Ca^2+^ imaging data revealed the dose-dependence of ES1 effects at the level of cytosolic Ca^2+^ and ER Ca^2+^. The area under the \[Ca^2+^\]~cyt~ surge induced by TG (post-TG area under the curve \[AUC\]), the \[Ca^2+^\]~ER~ levels before TG application (pre-TG \[Ca^2+^\]~ER~) and the half-times of the TG-induced decay in \[Ca^2+^\]~ER~ (post-TG t~1/2~) exhibited a strong dependence on ES1 concentrations in the 17-min treatments ([Figures 1](#fig1){ref-type="fig"}E--1G). Specifically, post-TG t~1/2~ showed the dose-dependent gain of Ca^2+^ leakage induced by ES1 ([Figure 1](#fig1){ref-type="fig"}G). Based on the analysis of post-TG AUC, pre-TG \[Ca^2+^\]~ER~ and post-TG t~1/2~, it can be estimated that the half maximal effective concentration (EC~50~) for the effects of ES1 on cytosolic and ER Ca^2+^ is approximately 1 μM ([Figures 1](#fig1){ref-type="fig"}E--1G). The low post-TG AUC values in the presence of 1 μM ES1 ([Figure 1](#fig1){ref-type="fig"}E) reflected mainly the shortening of the whole TG response ([Figure 1](#fig1){ref-type="fig"}A), which in turn paralleled the decrease of \[Ca^2+^\]~ER~ ([Figure 1](#fig1){ref-type="fig"}F) and the increase of the Ca^2+^ leak constant, seen as a shortening of post-TG t~1/2~ ([Figure 1](#fig1){ref-type="fig"}G). Thus, ES1 affects the product of \[Ca^2+^\]~ER~ and Ca^2+^ leak constant, i.e., the Ca^2+^ leakage. Following this reasoning, the time-dependent ES1 effects on Ca^2+^ leakage can be appreciated by comparing 4- and 17-min treatments. Cytosolic TG responses displayed similar amplitudes (post-TG Δ\[Ca^2+^\]~cyt~) after 4- and 17-min treatments with 1 μM ES1 ([Figure 1](#fig1){ref-type="fig"}H) despite lower \[Ca^2+^\]~ER~ levels after 17-min exposures ([Figure 1](#fig1){ref-type="fig"}I) because the Ca^2+^ leak constant increased with time, i.e., post-TG t~1/2~ values decreased (106.61 ± 7.72 versus 94.20 ± 6.50 s for 4- and 17-min treatments with 1 μM ES1, respectively).

Differential Effect of ES1 Analogs on ER Ca^2+^ {#sec2.2}
-----------------------------------------------

ES1 comprises two structural and functional distinct domains ([Figure 2](#fig2){ref-type="fig"}A): a 5-NF-containing domain and an aromatic domain ([@bib39], [@bib1], [@bib21]). In our present study, we have used the closely related analog ES2 and compounds ES24, ESR35, and ES47 ([Figure 2](#fig2){ref-type="fig"}A), collectively termed ESs which differ in either the aromatic or 5-NF domain ([@bib21]).Figure 2Comparison of the Effects of ES1 and Its Analogs ES2, ES24, ESR35, and ES47 on Cell Ca^2+^ Homeostasis(A) ES1 comprises an aromatic-rich domain and a domain that contains a 5-nitrofuran (5-NF) group. The ES1 analogs carry chemical modifications either in the aromatic domain (ES2, ES24) or in the 5-NF domain (ESR35, ES47).(B and C) The effects of ES2 on cytosolic (B) and ER (C) Ca^2+^ were mild compared with those of ES1, while ES24 rapidly depleted ER Ca^2+^ producing a robust accumulation of Ca^2+^ in cytosol.(D and E) ESR35 was ineffective at all and ES47 produced minute effects on cytosolic (D) and ER (E) Ca^2+^.(F) The area under the curve for TG responses shown in (A) were measured by integrating time courses of \[Ca^2+^\]~cyt~ between 1,200 and 1,800 s (post-TG AUC).(G and H) Half-times were determined for \[Ca^2+^\]~ER~ decays (G) after application of ES1, ES2, and ES24 (pre-TG t~1/2~) and (H) after the subsequent TG application in experiments shown in (C) (post-TG t~1/2~).(I and J) The area under the curve of TG responses in the experiments shown in (D) (post-TG AUC) (I) and the half-time of TG-induced decay of \[Ca^2+^\]~ER~ shown in (E) (post-TG t~1/2~) (J) were quantified for the time between 1,200 and 1,800 s.Time points of ES and TG application are indicated with vertical lines in (A--D) (mock/ES; 1 μM TG). Mock denotes DMSO controls. Data are presented as means ± SEM. n.a., not analyzed; n.s., not significant; \*p \< 0.05; \*\*\*p \< 0.001. N = 25--48 cells per experimental setting. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

ES1 enhanced Ca^2+^ leakage from the ER in a dose-dependent manner leading to a dose-dependent attenuation of the cytosolic responses to TG, seen as a decrease of post-TG AUC values ([Figure 1](#fig1){ref-type="fig"}). Using this paradigm for the action of ES1 on Ca^2+^ homeostasis and the online protocol, we analyzed the action of ES compounds at the highest concentration tested with ES1, namely 10 μM ([Figure 2](#fig2){ref-type="fig"}). The most obvious effects were seen immediately after application of ES1, ES2, and ES24 in the bath solution ([Figures 2](#fig2){ref-type="fig"}B and 2C). Strikingly, the increase of \[Ca^2+^\]~cyt~ was steeper and the decrease of \[Ca^2+^\]~ER~ faster upon treatment with ES24 than with either ES1 or ES2 ([Figures 2](#fig2){ref-type="fig"}B and 2C). Accordingly, the half-time of \[Ca^2+^\]~ER~ decay before TG application (pre-TG t~1/2~) was approximately two times shorter for ES24 than for ES1 at 10 μM ([Figure 2](#fig2){ref-type="fig"}G). Therefore, the ER was completely empty at the end of the 17-min treatment with ES24 and cytosolic TG responses were absent ([Figure 2](#fig2){ref-type="fig"}F), meaning that we were not able to estimate the actual increase in Ca^2+^ leakage induced by ES24, i.e., post-TG t~1/2~ ([Figure 2](#fig2){ref-type="fig"}H). As an alternative, we applied TG and ES24 simultaneously and found that this combination results in a 5-fold reduction in post-TG t~1/2~, suggesting that ES24 is a potent enhancer of Ca^2+^ leakage ([Figure S2](#mmc1){ref-type="supplementary-material"}). We also observed a continuous increase of \[Ca^2+^\]~cyt~ after 10--12 min exposure to ES24, pointing toward the risk of non-selective, cytotoxic effects of ES24 at prolonged exposures ([Figure 2](#fig2){ref-type="fig"}B). By contrast to ES24, the effects of ES2 on both \[Ca^2+^\]~cyt~ and \[Ca^2+^\]~ER~ were less pronounced than those of ES1 ([Figures 2](#fig2){ref-type="fig"}B and 2C). The pre-TG t~1/2~ for the decay of \[Ca^2+^\]~ER~ induced by ES2 was about twice as long as in the presence of ES1 ([Figure 2](#fig2){ref-type="fig"}G). Accordingly, the loss of ER Ca^2+^ and the Ca^2+^ accumulation in cytosol were less pronounced under the treatment with ES2 ([Figure 2](#fig2){ref-type="fig"}C) and cytosolic TG responses were detectable ([Figure 2](#fig2){ref-type="fig"}F). In contrast, ESR35, which has previously been used as an inactive control ([@bib8], [@bib21]), was largely ineffective on both \[Ca^2+^\]~cyt~ and \[Ca^2+^\]~ER~ ([Figures 2](#fig2){ref-type="fig"}D and 2E). ES47, however, displayed a small but statistically significant inhibition of Ca^2+^ leakage from ER ([Figure 2](#fig2){ref-type="fig"}I) that was paralleled by an increase in the post-TG half-time by circa 16% ([Figure 2](#fig2){ref-type="fig"}J).

The 5-NF Domain of ES1 Enhances Ca^2+^ Fluxes through Sec61 Complexes {#sec2.3}
---------------------------------------------------------------------

To examine the mechanism through which ES1 enhances Ca^2+^ leak, cells were depleted of Sec61α using small interfering RNA (siRNA). We performed these experiments in HeLa cells, in which silencing efficiencies of about 80% are routinely achieved ([@bib16]). Two independent siRNAs, *SEC61A1\#4* and *SEC61A1\#5*, were used to silence *SEC61A1*, and a scrambled siRNA (scr siRNA) was used as a control. Following our online protocol, HeLa cells were exposed to 10 μM ES1 and ES24, and the amplitude of cytosolic TG responses (post-TG Δ\[Ca^2+^\]~cyt~) was measured as an indicator for Ca^2+^ leakage ([Figures 3](#fig3){ref-type="fig"}A and 3B). In cells treated with either of two independent siRNAs, *SEC61A1\#4* and *SEC61A1\#5*A, we consistently observed lower peaks in the cytosolic responses to TG ([Figures 3](#fig3){ref-type="fig"}A and 3B), and the post-TG Δ\[Ca^2+^\]~cyt~ was about 35%--40% lower than in scr siRNA-treated cells ([Figures 3](#fig3){ref-type="fig"}C and 3D). Similar effects of *SEC61A1* silencing on cytosolic TG responses have been observed previously and were attributed to a decrease in Sec61-mediated Ca^2+^ leakage from ER ([@bib12]). Western blot analysis confirmed that the two siRNAs reduced the Sec61α subunit by circa 80%--82% in HeLa cells ([Figures 3](#fig3){ref-type="fig"}E and 3F). The cytosolic TG responses of scr siRNA-treated HeLa cells exposed to ES1 and ES24 peaked higher and were of shorter duration than mock treated cells ([Figures 3](#fig3){ref-type="fig"}A and 3B), as for HEK D1ER cells (cf. [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Accordingly, post-TG Δ\[Ca^2+^\]~cyt~ values were approximately 32% higher in the scr siRNA cells exposed to 10 μM ES1 ([Figures 3](#fig3){ref-type="fig"} A and 3C). However, 10 μM ES1 failed to increase post-TG Δ\[Ca^2+^\]~cyt~ in the cells treated with *SEC61A1\#4* or *SEC61A1\#5* ([Figures 3](#fig3){ref-type="fig"} A and 3C). Similarly, 1 μM ES24 enhanced post-TG Δ\[Ca^2+^\]~cyt~ values by about 62% in scr siRNA-treated cells but it was completely ineffective after silencing *SEC61A1* ([Figures 3](#fig3){ref-type="fig"} B and 3D). A potential explanation for this finding is that ES1 and ES24 were not effective after silencing *SEC61A1* because of low post-TG Δ\[Ca^2+^\]~cyt~ levels. As an additional control, we have therefore reduced the amplitude of cytosolic TG responses via an independent mechanism, namely by reducing SERCA protein levels to about 60% using *siRNA SERCA2*. Under these conditions, the levels of post-TG Δ\[Ca^2+^\]~cyt~ were as low as those measured after silencing *SEC61A1* and, remarkably, we found that 10 μM ES1 and 1 μM ES24 enhanced the cytosolic TG responses ([Figure S3](#mmc1){ref-type="supplementary-material"}). Thus, these results strongly suggest that the mechanism by which ES1 and ES24 disrupt cellular Ca^2+^ homeostasis is via a specific enhancement of Sec61-mediated Ca^2+^ leakage. Hence, we conclude that ER resident Sec61 complexes are targets for both ES1 and ES24.Figure 3siRNA-Mediated Silencing of *SEC61A1* Abolished the Effects of ES1 and ES24 on Ca^2+^ Homeostasis(A and B) The time courses of TG responses in cytosolic Ca^2+^ illustrate the loss of effects of ES1 (A) and ES24 (B) on Ca^2+^ leakage after silencing *SEC61A1* with two different siRNAs (*SEC61A1*\#*4* and *SEC61A15*). Experiments with control siRNA (scrRNA) and DMSO controls (mock) are superimposed for comparison. Application times are indicated by vertical lines (mock/ES1, mock/ES24, 1 μM TG).(C and D) Relative amplitudes of cytosolic TG responses (post-TG Δ\[Ca^2+^\]~cyt~) were used to quantify the effects of ES1 (C) and ES24 (D) in the experiments illustrated in (A and B), respectively.(E and F) Relative contents of Sec61α protein in cells treated with *SEC61A1* siRNAs are given as percentage of the Sec61α content in cells treated with *scrRNA* for the experiments with ES1 (E) and ES24 (F).Data obtained in six different silencing experiments are presented as means ± SEM. n.s., not significant; \*\*\*p \< 0.001. N = 94--222 cells per experimental setting. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Differential Effects of ES Compounds on Protein Degradation and ER Translocation {#sec2.4}
--------------------------------------------------------------------------------

ES1 interacts with the p97 complex and influences deubiquitinating processes that are mediated by p97-associated enzymes thereby inhibiting downstream proteasomal degradation and protein quality control ([@bib37]). One of the hallmarks of this effect is an accumulation of high-molecular-weight poly-ubiquitinated species in cells exposed to ES1 for several hours ([@bib37], [@bib21]), and we used this as a readout to compare the effects of our ES compounds on cellular ubiquitin homeostasis and related protein quality control processes. As described previously ([@bib37], [@bib21]), the treatment of HeLa cells with 8 μM ES1 induced a ∼3.4-fold increase of total poly-ubiquitinated species when compared with control cells ([Figures 4](#fig4){ref-type="fig"}A and 4B). Likewise, a substantial, accumulation of poly-ubiquitinated species was also observed in cells treated with ES2 ([Figures 4](#fig4){ref-type="fig"}A and 4B). In contrast, the effects of ES24 were by far less robust and, although a modest qualitative increase in signal was sometimes apparent ([Figure 4](#fig4){ref-type="fig"}A, cf. lanes 1 and 4), quantification showed that any changes were not statistically significant when compared with cells treated either with DMSO or ESR35 ([Figure 4](#fig4){ref-type="fig"}B). We speculate that the absence of any clear perturbation of ubiquitin homeostasis following treatment with ES24 reflects its lack of the distinct aromatic domain present in ES1 (cf. [Figure 2](#fig2){ref-type="fig"}A). This region is proposed to enhance the inhibitory effects of ES1 on the degradation of misfolded membrane proteins by targeting the compound to the ER where it may preferentially inhibit membrane-bound p97 ([@bib39]). ES47 was also ineffective at causing any accumulation of poly-ubiquitinated species ([Figure 4](#fig4){ref-type="fig"}B) and, since it lacks an intact 5-NF domain (cf. [Figure 2](#fig2){ref-type="fig"}A), our findings support the proposal that this region is important for ES1-mediated inhibition of p97 ([@bib39]). In summary, of the ES compounds that we analyzed, only ES1 and ES2 appear to cause the accumulation of endogenous poly-ubiquitinated species in HeLa cells, most likely via their inhibition of protein degradation ([@bib13], [@bib39], [@bib21]).Figure 4Differential Effects of ES1 Analogs on Protein Translocation and Degradation(A and B) HeLa cells were treated with ES1 analogs (8 μM) or with equal amounts of DMSO for 8 h. Cell lysates were analyzed by immunoblotting with an anti-ubiquitin (Ub) antibody (A). Ubiquitin signals were normalized relative to β-actin loading controls and normalized ubiquitin intensities are expressed relative to DMSO controls (B). The total levels of poly-ubiquitinated proteins were markedly increased in cells treated with ES1 and ES2 but not with ESR35 and ES47, while the effects of ES24 were not statistically significant compared with DMSO controls.(C and D) ES1, ES2, and ES24 reduced *in vitro* the glycosylation of a model membrane glycoprotein, the invariant chain (Ii) of the class II major histocompatibility complex, while ESR35 and ES47 had no inhibitory effect. Fully glycosylated Ii is denoted by li-2 Gly (C). Pancreatic ER ribosomes were pre-incubated for 1 h with ES1 analogs (250 μM) or with equal amounts of DMSO. Ratios of signal intensities li-2 Gly/Ii were used as a measure for total protein translocation and expressed relative to DMSO controls to estimate the relative ER processing (D).Quantifications are given as means ± SEM for three translocation experiments and six ubiquitination assays. n.s., not significant; \*p \< 0.05; \*\*p \< 0.01.

Since it has been shown that ES1 and ES2 inhibit Sec61-mediated protein translocation into the ER ([@bib8]), we studied the effects of our ES compounds using an -established cell-free membrane translocation assay. The histocompatibility leukocyte antigen (HLA) class II histocompatibility antigen gamma chain (Ii) was used as a model membrane glycoprotein, and its integration into ER-derived canine pancreatic microsomes that had been pre-incubated with the different ES compounds was investigated as described previously ([@bib8]). Hence, the efficiency of the Sec61-mediated translocation of the N-terminal domain of Ii into the ER lumen was determined by quantifying its N-glycosylation. As reported previously, ES1 and ES2 inhibited membrane translocation by ∼90% ([Figures 4](#fig4){ref-type="fig"}C and 4D), while ESR35 had no effect ([@bib8]). Strikingly, the effects of ES24 and ES47 on protein translocation mirrored their effects on Sec61-dependent Ca^2+^ leakage ([Figure 2](#fig2){ref-type="fig"}), and hence ES24 inhibited the N-glycosylation of Ii to a similar extent as ES1 and ES2, while ES47 had no effect ([Figures 4](#fig4){ref-type="fig"}C and 4D).

In summary, ES1 and ES2 efficiently inhibited both protein poly-ubiquitination *in cellula* and ER protein translocation *in vitro*, while ESR35 and ES47 showed no effect on either the ubiquitination or translocation assays ([Figure 4](#fig4){ref-type="fig"}). This suggests that ES1 and ES2 have at least two cellular targets within the protein homeostatic network. Firstly, the inhibition of protein translocation into the ER by ES1 and ES2 is most likely due to a direct effect on the Sec61 complex ([@bib8]). Secondly, ES1 and ES2 may influence de-ubiquitinating processes by interacting directly with p97 ([@bib37], [@bib21]). This dichotomy between Sec61- and p97-mediated effects is apparently absent in the cellular action of ES24, which efficiently inhibits ER translocation but has little if any effect on protein de-ubiquitination ([Figure 4](#fig4){ref-type="fig"}). Thus, our results suggest that ES24 selectively inhibits protein translocation at the ER, most likely by interacting with Sec61 complexes. This view is strongly supported by the enhancement of Sec61-dependent Ca^2+^ leakage that is observed when cells are treated with either ES1 or ES24.

Differential Effects of ES Compounds on Cell Death {#sec2.5}
--------------------------------------------------

ES1 has been shown to induce cell death in human blood cancer cell lines, and the 5-NF domain of ES1 was apparently pivotal to this cytotoxic effects ([@bib39], [@bib4]). To evaluate the role of ER Ca^2+^ leakage in the cytotoxicity of ES compounds, we next compared the sensitivities of various cell lines with ES1, ES24, and ESR35 ([Figure 5](#fig5){ref-type="fig"}). HEK, HeLa, INS-1, and NALM-6 cells were first exposed to these compounds for 24 h at concentrations ranging between 0.1 and 20 μM, and cell viability was then evaluated using the Guava ViaCount assay. As shown in [Figure 5](#fig5){ref-type="fig"}A, ES1 was toxic to all cell lines tested. As predicted from the lack of effect of ESR35 on Ca^2+^ flux and protein processing ([Figures 2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}), ESR35 was not toxic to the cell lines tested in the present study ([Figure 5](#fig5){ref-type="fig"}A). ES24 exhibited a surprisingly mild cytotoxicity on INS-1 and NALM-6 cells, and had no effect on the viability of HEK and HeLa cells at concentrations up to 20 μM ([Figure 5](#fig5){ref-type="fig"}A). Based on the well-defined effects of ES24 on Ca^2+^ leakage and protein translocation ([Figures 2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}) we hypothesized that, in contrast to the more complex effects of ES1 ([@bib39]), the cytotoxicity of ES24 may primarily reflect its effects on Sec61 complexes. To correlate the toxic effects of ES1 and ES24 with an enhancement of ER Ca^2+^ leakage, we determined the cell tolerance to the disruption of Ca^2+^ homeostasis by treatment with TG for 24 h. As with ES24, we found that HEK and HeLa cells were insensitive to TG (cell viability: HEK, 117.90% ± 3.32%; HeLa, 106.28% ± 2.90%), while INS-1 and NALM-6 cells were more prone to the effects of disruption of the Ca^2+^ homeostasis by TG (cell viability: INS-1, 81.46% ± 5.18%; NALM-6, 75.06% ± 5.20%). Combining the cell viability data for ES24 and TG, we observed a striking correlation between cell viabilities in the presence of ES24 and TG ([Figure 5](#fig5){ref-type="fig"}B), indicating that cell lines with high sensitivity to TG are also more sensitive to ES24. The effects of ES1 and ESR35 on cell viability were not correlated with the cell viabilities under TG treatment (not shown). Although our cytotoxicity studies did not address any potential contribution of the inhibition of protein translocation at ER, our data highlight the role of Sec61-mediated Ca^2+^ leakage in the cytotoxic effects of ES24 ([Figure 5](#fig5){ref-type="fig"}). Since TG prevents Ca^2+^ influx into the ER by inhibiting SERCA pumps, the TG effect can be seen as the counterpart of an enhancement of Ca^2+^ leakage. Therefore, the linear relationship between the cytotoxic effects of ES24 and TG shown in [Figure 5](#fig5){ref-type="fig"}B suggests that the actions of TG and ES24 may mechanistically converge on ER Ca^2+^ depletion. Conversely, the cytotoxic effects of ES1 may be dominated by p97 inhibition.Figure 5ES24 Reduces Cell Viability in a Ca^2+^-Dependent Manner(A) HEK, INS-1, HeLa, and NALM-6 cells were exposed for 24 h to various ES compounds (ES) and cell viability was measured as the percentage of living cells. While ES1 was cytotoxic to all cell lines, ESR35 was not cytotoxic at all and ES24 displayed mild effects on some cell lines.(B) Comparison of cell viabilities for 24-h treatments with 20 μM ES24 and 1 μM TG. A strong Ca^2+^-dependent component in cytotoxicity of ES24 is suggested by the linear correlation (black line) of the cell viabilities measured in the individual cell lines after 24 h treatment with 20 μM ES24 and 1 μM TG.Color and symbol coding for cell lines and substances are shown below panels. Cell viability was measured per duplicate in three independent experiments, normalized to DMSO controls and is presented as means ± SD.

Discussion {#sec3}
==========

Growing evidence indicates that Sec61 complexes become permeable for Ca^2+^ ions in the wake of protein translocation and generate a leakage of Ca^2+^ from ER ([@bib17]). Chemical modulators that inhibit protein translocation at the level of Sec61 complexes may, therefore, have an impact on ER Ca^2+^ leakage. Combining biochemical and functional assays, we show two diametrically opposed effects of ES1 on Sec61 complexes. ES1 inhibits protein translocation *in vitro* and enhances Sec61-mediated Ca^2+^ leakage *in cellula*. To gain insight into the mechanism behind the action of ES1 on Sec61 complexes, we compared various ES1 analogs and found that the 5-NF moiety of ES1 is critically involved in the effects on Sec61 complexes. Accordingly, ES24, which closely resembles the 5-NF moiety of ES1, displayed the strongest effects on Ca^2+^ leakage and the cytotoxic effects of ES24 were strongly Ca^2+^ dependent.

ES1 has been show to inhibit protein degradation at the level of p97, an effect that requires the 5-NF domain ([@bib39]). In this study, we observed an accumulation of poly-ubiquitinated species consistent with such an inhibition of protein degradation by ES1 ([Figure 4](#fig4){ref-type="fig"}). It is unclear whether these effects of ES1 on protein degradation disturb Ca^2+^ homeostasis in the ER, but, given that ES24 has a strong effect on Ca^2+^ leakage without a comparable effect on ubiquitin homeostasis, these processes may be distinct. Nevertheless, it is conceivable that the cellular accumulation of poly-ubiquitinated proteins over a period of hours may affect Ca^2+^ leakage. For instance, an increase in cytosolic Ca^2+^ levels is detected hours after exposure to proteasome inhibitors ([@bib40]). Notably, in the present study, we found that that ES1 enhanced ER Ca^2+^ leakage in a timescale of seconds to minutes ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, and [3](#fig3){ref-type="fig"}). Furthermore, silencing of *SEC61A1* abolished the ES1 effects on ER Ca^2+^ leakage completely ([Figure 3](#fig3){ref-type="fig"}), indicating that Sec61 complexes are central targets for the action of ES1 at the ER. Like ES1, ES2 and ES24 both enhance ER Ca^2+^ leakage ([Figure 2](#fig2){ref-type="fig"}) and inhibit protein translocation ([Figures 4](#fig4){ref-type="fig"}C and 4D; see also [@bib8]), and we assume that these effects also reflect the interaction of ES2 and ES24 with Sec61 complexes. Compared with ES1 and ES2, however, ES24 showed the strongest effects on ER Ca^2+^ leakage generating a robust response within seconds ([Figure 2](#fig2){ref-type="fig"}). Effects on Sec61-mediated Ca^2+^ leakage with a similar timescale have been described for inducers of ER stress and protein synthesis inhibitors ([@bib19], [@bib34], [@bib15], [@bib31]). Remarkably, a 10-min exposure to ES1 is also sufficient to observe a reduction in Sec61-mediated protein translocation, suggesting the ES1-mediated inhibition of this process is also a rapid event ([@bib8]).

The dual effects on Sec61 complexes of ES1, ES2, and ES24 ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}) indicate that active ES compounds prevent protein translocation into the ER while maintaining Sec61 complexes in a Ca^2+^-permeable state. Thus, the question arises as to how these apparently opposite effects on protein translocation and Ca^2+^ leakage can be reconciled in a mechanistic model for the action of ES compounds on Sec61 complexes. Using the crystal structure of canine Sec61α ([@bib36]), we modeled the structure of Sec61α in the open state ([Figure 6](#fig6){ref-type="fig"}A). According to the current view, Sec61α is formed by ten transmembrane helices arranged in two halves ([@bib28]). In the idle state, Sec61α is closed by the pore ring and the plug structure. After priming by the ribosome binding, the transmembrane helices rotate in a way that the lateral gate formed by transmembrane helices 2 and 7 is opened and the aqueous channel within Sec61α becomes free for protein translocation ([@bib36]). Docking analysis with the Sec61α structure revealed that ES1 interacts with Sec61α with a high affinity (ΔG = −9.62 kcal/mol). Specifically, the 5-NF group of ES1 interacts with H7 and H8 and occupies the volume between H2 and H7 ([Figure 6](#fig6){ref-type="fig"}B). Our model predicts that ES24 also binds with a high affinity (ΔG = −9.04 kcal/mol) and interacts with the N-terminal region of H7 ([Figure 6](#fig6){ref-type="fig"}C). Remarkably, the aromatic ring of ES24 and the 5-NF group of ES1 docked at the same place surrounded by H2, H7, and H8 at the cytosolic end of the lateral gate. Docking the 5-NF domain alone revealed that it also binds preferentially at the cytosolic end of the lateral gate ([Figure S4](#mmc1){ref-type="supplementary-material"}). This putative interaction site differs from the presumptive binding sites of other Sec61 inhibitors that have been proposed to stabilize the plug domain in a closed state and to prevent allosterically the opening of Sec61 complexes ([@bib35]). We have estimated the distance of these presumptive binding sites to the lateral gate and found that, with the exception of T86M, they are quite distant and, therefore, unlikely to affect the binding of ES compounds ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Docking analysis with a structural model of the T86M mutant predicted that T86M has only minor effects on the docking of ES1 and ES24 ([Figure S5](#mmc1){ref-type="supplementary-material"}B). The interactions of ES1 and ES24 with Sec61α are predicted to adopt rather central positions at short distances to the center of the H2-H7 gap (9.98 and 9.87 Å for ES1 and ES24, respectively). By contrast, the closest distance between ESR35 and the H2-H7 gap was calculated to be 15.06 Å, and the estimated affinity of its interaction with ESR35 is lower (ΔG = −7.91 kcal/mol). We do not know whether the interaction of ES1 and ES24 with Sec61α is reversible, but a parsimonious model suggests that these ES compounds interact with the helices forming the lateral gate and hamper conformational changes of Sec61α. This is equivalent to proposing that ES1 and ES24 promote an open, Ca^2+^-permeable, state of Sec61α by preventing the closing of the lateral gate ([Figure 6](#fig6){ref-type="fig"}D). Compared with other ion channels, this mechanism is quite unique in that ES compounds prevent closing and leave the Sec61α channel open for ion permeation. For instance, earlier studies on the action of small molecules on voltage-dependent Na^+^ channels have identified a foot in the door effect, in which the compound enters the open channel and prevents the gate from closing by binding within the pore (e.g., [@bib43]). In general, however, the consequence of such a foot in the door effect is that ion movements through the pore are blocked. Our model implies that ES compounds keep the lateral gate open as a foot in the door allowing Ca^2+^ ions to move freely through the aqueous channel present in Sec61α after protein translocation ([Figure 6](#fig6){ref-type="fig"}D).Figure 6Molecular Modeling of the Interactions of ES1 and ES24 with Sec61α(A) Homology model of the human Sec61α with the lateral gate in the open conformation. Lateral gate helices are highlighted in colors (H2 and H3, blue; H7 and H8, green). The triangle (yellow) shows the center of mass for the opening between H2 and H7. Overviews depict the Sec61α model seen from the plane of the membrane with the cytosolic side upward (upper panel, lateral gate in front) and from the cytosol (lower panel, cytosolic side in front).(B and C) Detailed pictures of the docking positions of ES1 (B) and ES24 (C) with the highest scores (ES1, ΔG = −9.62 kcal/mol; ES24, ΔG = −9.04 kcal/mol) in side views (upper panels) and top views (upper panels).(D) The proposed mode of action of ES1 and ES24 compounds (ES) on Sec61 complexes consider the binding of these compounds to Sec61α in the open state. Idle Sec61 complexes (i) are engaged in co-translational translocation processes upon binding of ribosome nascent chain complexes. Subsequently, the lateral gate of Sec61 complexes opens and the protein-conducting channel allows the translocation of the nascent chain (ii). After translocation, Sec61 complexes might adopt a Ca^2+^-permeable state with an aqueous channel that allows Ca^2+^ leakage from ER (iii). The cycle is closed when the ribosomes de-attach and Sec61 complexes return to the idle state. By binding to Sec61 complexes in the open state, ES compounds prevent the closing of the lateral gate with the consequence that Sec61 complexes are progressively captured in a Ca^2+^-permeable state (iv). For simplicity, only the channel-forming subunit (Sec61α) and the large ribosome subunit (60S) are depicted.See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

ES1 has been proposed as an anticancer agent ([@bib35]) and, accordingly, aqueous soluble derivatives of ES1 have been developed for cancer therapy ([@bib10]). As shown previously with multiple myeloma cell lines ([@bib4]), we found that the cytotoxicity of ES1 varied between cell lines. ES1 and ES24 not only enhanced the Sec61-mediated Ca^2+^ leakage from ER ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), but also inhibited protein translocation ([Figure 4](#fig4){ref-type="fig"}). Our model predicts that these ES compounds enhance the Ca^2+^ leakage in the short term and, in the long term, deplete the pool of translocation-competent Sec61 complexes and thereby restrict the process of co-translational protein translocation ([Figure 6](#fig6){ref-type="fig"}). We found that the gain of Ca^2+^ leakage induced by ES24 was the predominant mechanism in the cytotoxicity of the compound and that the degree of toxicity depends on cell type ([Figure 5](#fig5){ref-type="fig"}). Thus, our study identified ES24 as a small molecule that targets Sec61 complexes and causes cell-type-specific Ca^2+^-dependent cell death.

Significance {#sec4}
============

**Small molecules that target Sec61 complexes have been described as antimicrobial and anticancer agents (**[@bib35]**). While inhibition of protein translocation by these compounds has been a focus of research, their effects on the ion channel properties of Sec61 complexes are poorly understood. Sec61 complexes can support Ca**^**2+**^ **leakage from ER (**[@bib17]**), hence modulation of Sec61 gating may affect Ca**^**2+**^ **homeostasis in the cell. Here we show that inhibition of protein translocation by ES1 is associated with a gain of Sec61-mediated Ca**^**2+**^ **leakage from the ER lumen. Collectively, our data suggest that the 5-NF ring of ES1 slides into and obstructs the lateral gate, capturing Sec61 complexes in a Ca**^**2+**^**-permeable, open state. This unprecedented mechanism of action best resembles a "foot in the door" effect, in which ion channel closing is prevented without interference of the ion-conducting pathway. We have tested selected ES1 analogs and found that ES24, in which the chemical structure is basically reduced to the 5-NF domain of ES1, has higher selectivity toward Sec61 complexes than the parental ES1. Hence, among the ES1 analogs tested, ES24 showed the strongest effects on Sec61-mediated Ca**^**2+**^ **leakage and, consequently, the cytotoxic effects of ES24 were Ca**^**2+**^ **dependent. Thus, our work illustrates a strategy with therapeutic potential, namely one which targets cellular Ca**^**2+**^ **homeostasis by taking advantage of the ion channel properties of Sec61 complexes.**

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-Sec61 antibody (against the carboxy terminal peptide (14-mer) of human Sec61α)This studyN/AAnti-Serca2 ATPaseSigma-AldrichCat\# S1439; RRID: [AB_261442](nif-antibody:AB_261442){#interref110}Polyclonal anti-β-actin antibody\
Monoclonal anti-β-actin antibodyAbcam\
Sigma-AldrichCat\# Ab8227; RRID: [AB_2305186](nif-antibody:AB_2305186){#interref115}\
Cat\# A5441; RRID: [AB_476744](nif-antibody:AB_476744){#interref120}Mono- and polyubuitinylated conjugates monoclonal antibody (FK2)Enzo Life SciencesCat\# PW8810; RRID: [AB_10541840](nif-antibody:AB_10541840){#interref125}IRDye 680 RD Goat anti-Rabbit IgG (H + L) Secondary AntibodyLI-COR BiotechnologyCat\# 926-68071; RRID: [AB_10956166](nif-antibody:AB_10956166){#interref130}IRDye 800 RD Goat anti-Mouse IgG (H + L) Secondary antibodyLI-COR BiotechnologyCat\# 926-32210; RRID: [AB_621842](nif-antibody:AB_621842){#interref135}**Chemicals, Peptides, and Recombinant Proteins**Eeyarestatin 1 (ES1)This studyN/AEeyarestatin 2 (ES2)This studyN/AES24This studyN/AESR35This studyN/AES47This studyN/AThapsigarginThermoFisher ScientificT7459IonomycinThermoFisher ScientificI24222NigericinSigma-AldrichN71432-APBTocris524-95-8(-)-Xestospongin CTocris88903-69-9FURA-2 AMThermoFisher ScientificF1221Casein Blocking Buffer 10xSigma-AldrichB6429Puromycin dihyrochloride from Streptomyces *alboniger*Sigma-AldrichP7255Minimal Essential Medium (MEM)ThermoFidher Scientific31095-029Dulbecco's Modified Eagle's Medium (DMEM)ThermoFisher Scientific41966-029RPMI 1640ThermoFisher Scientific21875-034G418Sigma-AldrichG8168Foetal bovine serum (FBS)ThermoFisher Scientific11573397L-alanyl-L-GlutamineThermoFisher Scientific35050-038β-MercaptoethanolCarl Roth4227.3Sodium-PyruvateThermoFisher Scientific11360-070Amino Acid Mixture Minus MethioninePromegaL996AReticulocyte Lysate, Nuclease TreatedPromegaL416AEasyTag EXPRESS^35^S Protein Labeling Mix, \[^35^S\]PerkinElmerNEG7720002MCHiPerFect Transfection ReagentQiagen301705Guava ViaCountMerck4000-0041**Deposited Data**Human Sec61 subunit alpha, isoform 1[@bib11]UniProtKB: [P61619](uniprotkb:P61619){#intref0010}Canine Sec61 alpha 1 structure[@bib36]PDB: [3JC2](pdb:3JC2){#intref0015}Canine ribosome-bound Sec61 alpha 1 structure[@bib26]PDB: [5A6U](pdb:5A6U){#intref0020}Mouse P-glycoprotein structure[@bib2]PDB: [3G5U](pdb:3G5U){#intref0025}Human beta 2 adrenoreceptor structure[@bib29]PDB; [3P0G](pdb:3P0G){#intref0030}**Experimental Models: Cell Lines**HEKATCCCRL-1573HEK-D1ERThis studyN/AHeLaATCCCCL-2INS-1[@bib3]N/ANALM-6DSMZACC-128**Oligonucleotides***SEC61A1*\#4 siRNA: GGAAUUUGCCUGCUAAUCAttQiagenN/A*SEC61A1*\#5 siRNA: CACUGAAAUGUCUACGUUUttQiagenN/AAllStars Negative Control siRNAQiagen1027285*SERCA2* siRNAThermoFisher Scientific120744Silencer Negative ControlThermoFisher ScientificAM4611**Recombinant DNA**pcDNA3-D1ER[@bib25]Addgene: 36325cDNA coding for residues 17 to 232 of the short form of human HLA class II histocompatibility antigen gamma chain (Ii)[@bib7]UniProtKB: [P04232-2](uniprotkb:P04232-2){#intref0035}**Software and Algorithms**Live AcquisitionTill Photonics<https://www.fei.com/service-support/Light-Microscopy/>AIDA v5.0Elysia Raytest<http://www.elysia-raytest.com/de/cataloglight/>Matlab R2015bMathworks<https://de.mathworks.com/products.html>MODELLER 9.17[@bib20]<https://salilab.org/modeller/download_installation.html>NAMD[@bib27]<http://www.ks.uiuc.edu/Development/Download/download.cgi?PackageName=NAMD>Pro-Sa-web[@bib41]<https://prosa.services.came.sbg.ac.at/prosa.php>AutoDock4[@bib23]<http://autodock.scripps.edu/downloads>

Contact for Reagent and Resources Sharing {#sec5.2}
-----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Adolfo Cavalié (<Adolfo.cavalie@uks.eu>).

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

HEK cells (human epithelial embryonic kidney cells, ATCC) were cultivated in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) foetal bovine serum (FBS). In order to obtain cells with homogenous expression levels of the FRET-based Ca^2+^-sensor D1ER, we generated the stable cell line HEK D1ER by transfecting HEK cells with the plasmid pcDNA3-D1ER ([@bib25]), which was kindly provided R. Y. Tsien (University of California San Diego, La Jolla, USA). HEK-D1ER cells were maintained in culture under selection with G418 (0.5 mg/ml) in Minimal Essential Medium (MEM) supplemented with 10% (v/v) FBS. HeLa cells (human epithelial cervix carcinoma cells, ATCC, female) were cultured in DMEM supplemented with 10% (v/v) FBS and 2 mM *L*-alanyl-*L*-glutamine. NALM-6 (human B-cell precursor leukaemia cells, DSMZ, male) were cultured in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated FBS. INS-1 cells are derived from rat insulinoma ([@bib3]) and were kindly provided by P. O. Berggren (Karolinska Institute, Stockholm, Sweden). The culture medium of INS-1 cells was RPMI 1640 supplemented with 10% (v/v) heat-inactivated FBS, 50 μM β-mercaptoethanol and 1 mM Na-pyruvate. All cell lines were maintained in a 5% CO~2~ humidified incubator at 37°C.

Method Details {#sec5.4}
--------------

### Synthesis of Eeyarestatin (ES) Compounds {#sec5.4.1}

The compounds ES1, ES2 and ESR35 were synthesized as previously described ([@bib21]).

ES24 and ES47 were prepared in good yields by condensation of acyl hydrazides **1** and **2** with the appropriate conjugated aldehyde. Phenylacetic hydrazide **1** is commercially available and the synthesis of **2** (ESR35) has been reported previously ([@bib8]). The double bond geometry in both compounds was confirmed by the magnitude of the corresponding vicinal ^1^H-^1^H coupling constant (15.9 Hz for ES24 and 14.8 Hz for ES47).

General experimental synthetic reagents and solvents were purchased from Sigma-Aldrich or Alfa Aesar and used as supplied. IR spectra were recorded on a Perkin Elmer 881 spectrometer, an AT1-Matson Genesis Series FTIR spectrometer or a Perkin Elmer Spectrum BX FTIR spectrometer. ^1^H NMR spectra were recorded on a Bruker Avance II 500MHz spectrometer. Chemical shifts are referenced to the residual solvent peak. Mass spectra were recorded on a Micromass Platform II (electrospray) spectrometer. Melting points were recorded using a Sanyo Gallenkamp MPD350 heater and are uncorrected.

#### 2-{2-\[3-(5-nitro-2-furyl)-2-propen-1-ylidene\]hydrazino}-2-oxoethylbenzene (ES24) {#sec5.4.1.1}

(*E*)-3-(5-Nitro-2-furyl)acrylaldehyde (128 mg, 0.77 mmol) was added, under nitrogen, to a solution of phenylacetic hydrazide (115 mg, 0.77 mmol) in anhydrous CH~3~OH (4 mL). The reaction mixture was stirred at room temperature overnight and then Et~2~O was added to allow complete precipitation to occur. The solid was collected by filtration and washed with Et~2~O and pentane, yielding the title compound (196 mg, 85%) as a yellow solid. Mp 202-204°C; ν~max~ (evaporated film)/cm^-1^ 3137 (w, N-H), 3040 (w, C-H), 2971 (brw, C-H), 2857 (brw, C-H), 1747 (w, C=O), 1667 (s, C=C), 1587 (m, C=C), 1557 (m, C=C), 1504 (s, C=C); ^1^H NMR (CDCl~3~; 500 MHz) δ 4.03 (2H, s, C(1)H~2~), 6.63 (1H, br, C(7)H), 6.65 (1H, d, *J* = 15.9 Hz, C(5)H), 7.15 (1H, dd, *J* =15.9, 9.5 Hz, C(4)H), 7.33-7.37 (6H, m, C(8)H & Ar-CH), 7.51 (1H, d, *J* = 9.5 Hz, C(3)H); *m/z* (-ve ion electrospray) 298 (\[M-H\]^-^, 100%), (+ve ion electrospray) 322 (\[M+Na\]^+^, 100%); found 322.0805, C~15~H~13~N~3~O~4~Na (\[M+Na\]^+^), requires 322.0798.

#### N'-(4-Chlorophenyl)-N-\[3-(4-chlorophenyl)-2-oxo-1-(2-{2-\[3-(2-furyl)-2-propen-1-ylidene\]hydrazino}-2-oxoethyl)-5,5-dimethyl-4-imidazolidinyl\]-N-hydroxyurea (ES47) {#sec5.4.1.2}

(*E*)-3-(2-Furanyl)acrylaldehyde (49 mg, 0.4 mmol) was added, under nitrogen, to a solution of **2** (96 mg, 0.2 mmol) in anhydrous CH~3~OH (1 mL). The reaction mixture was stirred at room temperature for 2 days and then concentrated under reduced pressure. The residue was recrystallised at room temperature from Et~2~O /pentane, yielding the title compound (86 mg, 73%) as a pale yellow solid. Mp 213-214.5°C; ν~max~ (solid state)/cm^-1^ 3395 (w, O-H), 3222 (brw, N-H), 3145 (brw, N-H), 3132 (brw), 3039 (w, C-H), 2979 (w, C- H), 2974 (w, C-H), 2930 (w, C-H), 1699 (m, C=O), 1680 (s, C=O), 1661 (s, C=O), 1633 (m, C=C), 1588 (w, C=C), 1550 (s, C=C), 1512 (m, C=C); ^1^H NMR (CDCl~3~; 500 MHz) δ 1.31 (3H, s, C(19)H~3~ or C(20)H~3~), 1.40 (3H, s, C(19)H~3~ or C(20)H~3~), 4.41 (2H, ABq, *J*~*AB*~ = 18.7 Hz, C(21)H~2~), 5.75 (1H, d, *J* = 14.8 Hz, C(25)H), 6.10 (1H, s, C(3)H), 6.29 (1H, d, *J* = 3.1 Hz, C(27)H), 6.38 (1H, dd, *J* = 3.1, 1.7 Hz, C(28)H), 6.59 (1H, dd, *J* = 14.8, 7.9 Hz, C(24)H), 7.17 (4H, m, Ar-CH), 7.20-7.25 (1H, m, C(23)H), 7.40 (1H, br, C(29)H), 7.47 (4H, m, Ar-CH), 7.78 (1H, brs, NH or OH), 9.41 (1H, brs, NH or OH), 9.75 (1H, brs, NH or OH); *m*/*z* (−ve ion electrospray) 587 (\[M−H\]^-^, (^37^Cl,^37^Cl), 10%), 585 (\[M−H\]^-^, (^35^Cl,^37^Cl), 65%), 583 (\[M−H\]^-^, (^35^Cl,^35^Cl), 100%); (+ve ion electrospray) 611 (\[M+Na\]^+^, (^37^Cl, ^37^Cl), 10%) 609 (\[M+Na\] ^+^, (^35^Cl,^37^Cl), 60%), 607 (\[M+Na\] ^+^, (^35^Cl,^35^Cl), 100%); (Found 607.1244, C~27~H~26~^35^Cl~2~N~6~NaO~5~, (\[M+Na\]^+^), requires 607.1234).

### *In Vitro* Translocation Assay {#sec5.4.2}

Nuclease-treated canine pancreatic microsomes were treated with 250 μM ESR35, ES1, ES2, ES24, ES47 (from 1 mM stock solutions in DMSO), or an equal volume of DMSO, and incubated on ice for 1 h before inclusion in translocation analyses. Cell-free translation (20 μL) was performed in nuclease-treated rabbit reticulocyte lysate (Promega) in the presence of EasyTag EXPRESS ^35^S Protein Labelling Mix containing \[^35^S\] methionine (Perkin Elmer) (0.611 MBq; 40.95 TBq/mmol), ∼2.5% (v/v) amino acids minus methionine (Promega), 9% (v/v) *in vitro* transcribed mRNA (290 ng/μL stock) encoding residues 17 to 232 of the short form of human HLA class II histocompatibility antigen gamma chain (Ii) and 10% (v/v) inhibitor/DMSO pre-treated rough microsomes for 20 min at 30°C. The short form of Ii was kindly provided by Dr. B. Dobberstein (ZMBH, Heidelberg University, Heidelberg, Germany). Following translation, puromycin was added to 0.1 mM and samples incubated for 5 min at 30°C to ensure ribosomal release. The membrane-associated fraction of the reaction was isolated by centrifugation (100,000 *g* for 10 min at 4°C in a TLA100 rotor (Beckmann) through an 80 μL high-salt cushion (0.75 M sucrose, 0.5 M KOAc, 5 mM Mg(OAc)~2~, 50 mM Hepes-KOH, pH 7.9) and the membrane pellet suspended in 30 μL SDS sample buffer (0.02% bromophenol blue, 62.5 mM, 4% (w/v) SDS, 10% (v/v) glycerol; pH 7.6; 1 M dithiothreitol). Samples were denatured at 70°C for 5 min prior to resolution by SDS-PAGE (10 μL sample, 16% polyacrylamide gels, 120 V, 120 min). Gels were incubated in fix mix (20% MeOH, 10% AcOH) for 5 min, dried (BioRad Gel Dryer) for 2 h at 65°C and exposed to a phosphore imaging plate for 24 h. Radiolabelled products were visualized using a Typhoon FLA-7000 (GE Healthcare). Quantitative analysis was performed with AIDA v5.0 (Raytest Isotopenmeβgeräte) whereby the signal intensity of Ii-2 Gly/Ii was used as a read-out for total translocation and expressed relative to the DMSO control to determine the mean relative ER processing from 3 independent experiments. Data is presented as mean ± SEM.

### *In Cellula* Ubiquitination Assay {#sec5.4.3}

Experiments performed whit HeLa cells cultured to ∼80% confluent. DMEM was aspirated from each well 16 h after cell plating and cells treated with 8 μM ES1, ES2, ES24, ESR35 and ES47 (from 10 mM stock solutions in DMSO), or an equal volume of DMSO, in 1 mL fresh DMEM for 8 h. Upon treatment completion, DMEM was aspirated, cells washed twice with PBS (Dulbecco's Phosphate Buffered Saline) and solubilized in 100 μL SDS sample buffer. Samples were denatured for 16 h at 37°C, resolved by SDS-PAGE (20 μL sample, 10% polyacrylamide gels, 120 V, 100 min) and proteins transferred to a PVDF membrane in transfer buffer (0.08 M Tris base, 0.60 M glycine, 20% MeOH) at 300 mA for 2.5 h at ambient temperature. The membrane was blocked in Casein blocking buffer (Sigma) diluted in TBS (Tris Buffered Saline; 0.2 M Tris base and 1.5 M NaCl; pH 7.4) for 1 h at ambient temperature prior to primary antibody (FK2 mouse (Enzo Life Sciences) and β-actin (Abcam)) incubation in Casein blocking buffer diluted 1:10 in TBST (TBS supplemented with 0.1% Tween-20) for 16 h at 4°C. After washing with TBST (4 x 10 min), the membrane was then incubated with a fluorescent secondary antibody for 1 h at ambient temperature. Following washing with TBST (4 x 10 min), samples were visualized using an Odyssey CLx Imaging System (LICOR Biosciences). Ubiquitin signals were normalized relative to the intensity of the β-actin loading control and normalized signals expressed relative to the DMSO solvent control. Data is shown as mean ± SEM from 6 independent experiments.

### Gene Silencing {#sec5.4.4}

Silencing of *SEC61A1* was performed in HeLa cells as previously described ([@bib16]). Briefly, 5.2 x 10^5^ HeLa cells were seeded per 6-cm culture plate transfected with *SEC61A1*\#4 (GGAAUUUGCCUGCUAAUCAtt, Qiagen) or *SEC61A1*\#5 siRNA (CACUGAAAUGUCUACGUUUtt, Qiagen) or scramble siRNA (AllStars Negative Control siRNA, Qiagen) using HiPerFect Reagent (Qiagen). After 24 h, cells were transfected for a second time. Ca^2+^ imaging experiments were performed 96 h after beginning of transfection. Silencing efficiencies were evaluated by Western blot analysis using the respective antibodies and an anti-β-actin-antibody from mice ([@bib31]). For silencing of SERCA2, HeLa cells were transfected with 30 μM *siRNA SERCA2* (GCGGAUUAAAGCUAAAGACtt, Thermo Fisher) or with 30 μM *scr RNA* (Silencer Negative Control, Thermo Fisher) using HiPerFect (Qiagen). Ca^2+^ imaging experiments were performed 24 h after transfection. *SERCA2* expression levels were detected with a SERCA2 antibody (S1439, Thermo Fisher).

### Live Cell Calcium Imaging {#sec5.4.5}

\[Ca^2+^\]~ER~ and \[Ca^2+^\]~cyt~ were imaged using D1ER and FURA-2, respectively. D1ER is a genetically encoded FRET-based Ca^2+^ sensor that comprises two fluorescent proteins, CFP and citrine, and two sensing proteins, a calmodulin-binding peptide derived from skeletal muscle myosin light chain kinase and calmodulin ([@bib25]). D1ER was stably expressed in HEK cells. FURA-2 is a ratiometric dye that localizes to the cytosol (see [@bib16]). For simultaneous measurements of \[Ca^2+^\]~ER~ and \[Ca^2+^\]~cyt~, HEK-D1ER cells were loaded with the membrane-permeable FURA-2 AM just before each Ca^2+^ imaging experiment (see [@bib16]). In order to prevent the Ca^2+^ entry from the extracellular space, all Ca^2+^ imaging experiments were carried out with a Ca^2+^-free bath solution (140mM NaCl, 5mM KCl, 1mM MgCl2, 0.5 mM EGTA, 10 mM glucose in 10 mM HEPES-KOH, pH 7.35). Accordingly, D1ER and FURA-2 reported changes in \[Ca^2+^\]~ER~ and \[Ca^2+^\]~cyt~, respectively, which arose from Ca^2+^ mobilisation within internal cell compartments. Ca^2+^ imaging experiments were performed with cells that were plated on poly-L-lysine-coated cover slips and cultured for 48-72 h.

Ca^2+^ imaging experiments were carried out with the iMIC microscope, the polychromator V, and the Live Acquisition software (Till Photonics). To allow the recording of D1ER and FURA-2 signals in the same cells, the filter sets were automatically exchanged. Firstly, D1ER was excited by exposing HEK D1ER cells at 433 nm. The emitted florescence was then split at 469/23 nm and 536/27 nm to obtain the CFP and citrine components, respectively. The cell fluorescence was additionally passed through a dichrotome and projected on the chip of the microscope camera to obtain simultaneous CFP and citrine images. Secondly, FURA-2 was excited by alternated excitation at 340 and 380nm. The emitted fluorescence also passed through a dichrotome and captured at 510 nm to obtain FURA-2 images at 340 and 380 nm excitation. D1ER and FURA-2 image pairs containing 5--10 cells/frame were obtained every 10-12 s. D1ER ratios were calculated from CFP and citrine image pairs as F536/F469, where F536 and F469 represent the background-subtracted citrine and CFP fluorescence intensities, respectively. FURA-2 signals were measured in FURA-2 image pairs as F340/F380, where F340 and F380 correspond to the background-subtracted fluorescence intensity at 340 and 380 nm excitation wavelengths, respectively. Following corrections for bleed-through, F536/F469 and F340/F380 were used to calculate \[Ca^2+^\]~ER~ and \[Ca^2+^\]~cyt~, respectively (see [@bib33], [@bib16]). Basically, free Ca^2+^ concentrations were calculated with the standard ratiometric equation \[Ca^2+^\]~free~ = βK~d~⋅((R-R~min~)/(R~max~-R)) (see [@bib16]), in which we replaced R by the ratios F536/F469 and F340/F380 to obtain \[Ca^2+^\]~ER~ and \[Ca^2+^\]~cyt~, respectively. In this equation, the apparent K~d~ of the Ca^2+^ sensors is represented by βK~d~ and was obtained by measuring F536/F469 ratios in HEK-D1ER cells that were exposed to 10 μM ionomycin, 10 μM nigericin and free Ca^2+^ concentrations between 1 μM and 10 mM. Fitting of the calibration data with the standard ratiometric equation reveal a βK~d~ of 165.25 μM for D1ER in our imaging system. βK~d~⋅was 5.26 μM for FURA-2 in our imaging system. Maximal and minimal fluorescence ratios of the Ca^2+^ sensors are given by R~min~ and R~max~ in the standard ratiometric equation, respectively, HEK-D1ER cells were exposed to 10 μM ionomycin and the R~max~ of D1ER signals was measured as the maximal F536/F469 ratio in the presence of 25 mM Ca^2+^. Conversely, the R~min~ of D1ER signals was the minimal F536/F469 ratio measured in the presence of 0.5 mM EGTA. The R~max~ and R~min~ of FURA-2 signals were determined in FURA-2 loaded HEK-D1ER cells as previously described (see [@bib16]). HeLa cells were used to image only cytosolic Ca^2+^ in gene silencing experiments and, accordingly, \[Ca^2+^\]~cyt~ was imaged with FURA-2 as previously described (see [@bib16]).

Stock solution of ES compounds were prepared by dissolving the compounds ES1, ES2, ES24, ESR35 and ES457 in DMSO to obtain concentrations of 10-100 mM. Stock were maintained frozen at -20°C. Similarly, 1 mM stocks of thapsigargin were prepared in DMSO. Just before experiments, stocks of TG and ES compounds were diluted to a 2X concentration in the bath solution, i.e., 2 times greater than the desired final concentration. Routinely, TG and ES compounds were applied to the cells during Ca^2+^ imaging by adding 2X solutions to the bath at a ratio of 1:1 to avoid problems arising from slow mixing. The final DMSO concentration in bath was 0.01-0.05 % v/v. During Ca^2+^ imaging, a base line was routinely recorded before applying ES compounds in order to determine the status of \[Ca^2+^\]~cyt~ and \[Ca^2+^\]~ER~. In the so-called "online" protocol, ES compounds were applied at 3 min while imaging was running. Mock treatment represents the application of 0.01--0.05% v/v DMSO in bath solution. Following 1, 4 and 17 min exposures to eeyarestatin compounds, TG was applied in bath to unmask the Ca^2+^ leakage from ER. In experiments with D1ER and FURA-2, 5-10 HEK D1ER cells were imaged simultaneously, while 30-50 HeLa cells were imaged per experiment with FURA-2. Time courses of \[Ca^2+^\]~ER~ and/or \[Ca^2+^\]~cyt~ were constructed for each experiment and parameters such as the area under the curve and amplitude of TG responses were measured for each single cell. Ca^2+^ imaging experiments were performed with 3-5 different batches of HeLa and HEK D1ER cells. Data has been collected in 6-12 independently experiments repeated for each experimental setting and is shown as mean ± SEM.

### Cell Viability Assay {#sec5.4.6}

HEK, HeLa, INS-1 and NALM-6 cells were plated in culture dishes at densities between 0.25-0.50⋅10^6^ cells/ml in the respective culture medium and treated with ES1, ES24 and ESR35 at concentrations between 1-20 μM for 24 h. Similarly, cells were treated with 1 μM thapsigargin for 24 h. The DMSO concentration was 0.1 % in TG-containing medium and below 0.02 % in medium with ES compounds. Following treatment, cells were incubated with PBS and Guava ViaCount reagent (1:10) for 5 min in the dark at room temperature. Cell viability was measured by flow cytometry with Guava easyCyte 8HT (Merck Millipore). Viability measurements were performed as duplicates in 3 independent experiments per treatment with 5000 cells/measurement. The cell viability of cells exposed to ES1, ES24 and ESr35 was normalised with respect to the viability of non-treated cells. For cells exposed to TG, cell viability was normalised to 0.1 % DMSO controls. Normalised viability data is presented as mean ± SD.

### Homology Modelling and Docking Protocols {#sec5.4.7}

The protein sequence of human Sec61α isoform 1, which contains 476 amino acids, was retrieved from the UniProtKB database (UniProt: [P61619](uniprotkb:P61619){#intref0080}). The crystal structure of canine Sec61α (PDB: [3JC2](pdb:3JC2){#intref0085}) was selected for homology modelling of human Sec61α. Both sequences share 99.8% sequence identity. The 3JC2 structure shows Sec61α in an open conformation but is lacking structural information for the helical plug region (residue 63 to 69). Since in the open conformation, the plug is believed to be outside of the translocation pathway, we assumed that it does not form relevant interaction with the substrates. Homology modelling was carried out using the MODELLER 9.17 package. The plug region was modelled and optimised as a loop structure. Subsequently, the homology model was subjected to energy minimization, using the NAMD package, to relax side chain atoms. The resulting model ([Figure 6](#fig6){ref-type="fig"}A) was validated by the ProSa-web server, along with two Sec61α structures (PDB: [3JC2](pdb:3JC2){#intref0090} and PDB: [5A6U](pdb:5A6U){#intref0095}) and two other membrane protein structures: a GPCR (PCB: 3P0G) and an ABC transporter (PDB: [3G5U](pdb:3G5U){#intref0100}). The analysis from ProSa-web showed that the score of the homology model is within the range of scores typically found in experimentally determined structures of protein chains. The structural model of Sec61 α carrying the T86M mutation was generated by Swiss-Pdb Viewer and subsequent minimization with NAMD.

The protonation states of protein residues and partial charges of ligands were assigned by the *prepare_receptor* and *prepare_ligand* modules of the AutoDock4 package. For each ligand, the docking calculations were performed in 2 consecutive steps: In the first docking step, we adopted a relatively large grid box covering the entire cavity of Sec61, to scan for energetically favourable conformations of the ligand inside the Sec61 pocket. The Lamarckian genetic algorithm was used for the optimization of the ligand conformations and orientations (cubic box of 45 Å, grid spacing, 2.5×10^6^ energy evaluations and 27 ×10^3^ generations). In the second docking step, the size of the grid box was scaled down based on the population of the most stable binding positions of the ligand. In a finer run, more stringent parameters (cubic box of 34 Å, 100×10^6^ energy evaluations and 0.5×10^6^ generations) were used.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

Quantification procedures used *in vitro* and *in cellula* experiments as well as in Ca^2+^ imaging experiments are described in [Method Details](#sec5.4){ref-type="sec"}.

The statistical significance of *in vitro* and *in cellula* data with respect to DMSO controls was determined using Tukey's and Dunnett's multiple comparison tests, respectively. Statistical significance of the Ca^2+^ imaging data was assessed with the two-sample Kolmogorov-Smirnov test. Statistical significance is given as n.s., non-significant; \*, P \< 0.05; \*\*, P \< 0.01 and \*\*\*, P \< 0.001.

Data and Software Availability {#sec5.6}
------------------------------

*In vitro* data was analysed with AIDA. Matlab was used in the analysis of Ca^2+^ imaging data. Homology modelling and docking analysis were performed with Modeller 9.17, NAMD, Pro-Sa-web and AutoDock4.
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